Exhibit 16.1
April 3, 2026
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Items 4.01(a) and 4.01(b) of Arcadia Bioscience, Inc.’s Form 8-K dated April 3, 2026, and have the following comments:
1.
We agree with the statements made in Item 4.01(a).
2.
We have no basis on which to agree or disagree with the statements made in Item 4.01(b).
Yours truly,
/s/ Deloitte & Touche LLP